Navigation Links
Secrets of cellular signaling shed light on new cancer stem cell therapies

ANN ARBOR, Mich.---By revealing the inner workings of a common cell-to-cell signaling system, University of Michigan biologists have uncovered new clues about mysterious and contentious creatures called cancer stem cells.

The findings also have implications for a high-profile breast-cancer drug trial getting underway at the U-M Medical School and two other institutions.

In the groundbreaking trial, researchers are combining chemotherapy with a drug that blocks the Notch signaling pathway, which helps regulate fetal development and is active in most organ systems throughout a person's life.

The aim is to use so-called Notch inhibitors to attack cancer stem cells, the small fraction of stem cells inside a tumor that help it survive and that fuel its growth.

But a big concern is that the Notch inhibitors, while helping to destroy cancer stem cells, might also kill or harm the normal, healthy stem cells critical to a patient's survival such as blood-forming stem cells in the bone marrow.

New results from the U-M's Dr. Ivan Maillard and his colleagues may allay some of those fears. The researchers showed that blood-forming stem cells in mice survive just fine when the Notch signaling pathway is experimentally blocked.

"Our data indicate that normal blood-forming stem cells should not be damaged by the Notch inhibitor drug being used in these patients," said Maillard, a hematologist and a Life Sciences Institute researcher.

"That's important, since these patients typically need good blood stem cells to maintain their blood counts and recover from the effects of chemotherapy," he said.

The Notch findings will be published Thursday in the journal Cell Stem Cell. Maillard's team includes researchers from the University of Pennsylvania School of Medicine, the Swiss Institute for Experimental Cancer Research, and Harvard Medical School.

Dr. Max Wicha, director of the U-M Comprehensive Cancer Center, said Maillard's results are welcome news for cancer stem cell researchers, and for the 30-patient metastatic breast-cancer drug trial that launched last month at his center, at the Baylor College of Medicine in Houston, and at the Dana-Farber Cancer Institute in Boston.

"It's really important, because a lot of what we're thinking about now, therapeutically, is trying to find ways to attack these cancer stem cells, because we think that's really what drives the malignancies," said Wicha, who was not involved in the Notch study.

"Ivan's paper, combined with our own work, shows that there may be differences between normal stem cells and cancer stem cells, and perhaps those differences can be exploited therapeutically," Wicha said.

The cancer stem cell theory is controversial. Some researchers are not convinced that cancer stem cells exist.

The current two-stage drug trial uses a Notch inhibitor originally developed by Merck for Alzheimer's patients in the late 1990s, followed by chemotherapy. The intent is to use the Notch inhibitor to make cancer stem cells sensitive to the chemotherapy---a one-two punch to knock out tumors.

If the treatment is effective, the results could help sway some cancer-stem-cell skeptics.

The Notch pathway sends signals from a cell's surface membrane into its nucleus. Those signals activate genes that instruct the cell to make proteins that perform various tasks.

In the lab, Maillard and his colleagues were able to prevent Notch signals from activating mouse target genes using two independent techniques.

Many scientists have long assumed that blood-forming stem cells need Notch signals to function properly. But Maillard's team found that the signals are not required for the maintenance of blood-forming stem cells in adult mice.


Contact: Jim Erickson
University of Michigan

Related medicine news :

1. Scientists Probe Sepsis Deadly Secrets
2. The Well Life Center in Mesa Unveils The 10 Healing Secrets to Health & Longevity Lecture. Proceeds Benefit The Arizona Special Olympics
3. UPCARE Technology to Share the Secrets of its Parents Success in Lab Outreach
4. Mathematicians help unlock secrets of the immune system
5. New Survey Uncovers Dirty Little Secrets About Americas Oral Care Habits
6. The Well Life Center in Mesa Continues The 10 Healing Secrets to Health & Longevity Lecture. Proceeds Benefit The Arizona Special Olympics
7. Secrets to Long-Lasting Marriages Revealed in Senior Survey
8. Oscar Makeover CHEAT Secrets of the Stars Revealed
9. HealthBarn(R) USA Founder Shares Secrets For Healthy Eating With Rachael Ray
10. Dr. Rovenia Brock Brings Secrets of Living Healthy to Susan G. Komen for the Cure(R)s Circle of Promise
11. Story ideas from molecular & cellular proteomics
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 ... semi-finalists to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic ... Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture ...
(Date:12/1/2015)... ... ... With FCPX Overlay: Grit , users can apply a grit effect ... truly endless, all with a click of a mouse. Each user has full control ... of field and more, all within Final Cut Pro X. , With FCPX Overlay: ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Magazine as a Modern Man for 2015. , Angeleno Magazine is a ... United States. Established in 1994, Modern Luxury includes more than 50 magazine titles ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as ... Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Olympic Gold Medalists ... collaborating with brands across various categories through traditional and social media marketing campaigns ... elite group of Gold Medal Moms who can connect with today’s most important ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
(Date:12/1/2015)... , December 1, 2015 ... of eye and gaze tracking solutions, today announced that ... trackers as a component of its revolutionary new vision ... and medical and performance issues in patients. The new ... mass-market-ready eye tracking platform, which is ready to be ...
(Date:12/1/2015)... Dec. 1, 2015  Lexicon Pharmaceuticals, Inc. ... top-line data from its TELECAST Phase 3 ... treating carcinoid syndrome in cancer patients with ... benefit observed in its pivotal TELESTAR study.  ... companion to TELESTAR primarily to provide additional ...
Breaking Medicine Technology: